December 10, 2025
Johannes Jungwirth, Samuel Westenhöfer, Helena Aicher et al.
Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical trials. However, its effectiveness and safety in real-world therapeutic settings remain largely unknown. Although psilocybin is not yet approved as an antidepressant treatment, Switzerland’s unique legal framework allows its limited medical use for...
European Archives of Psychiatry and Clinical Neuroscience
September 1, 2025
Golo Kronenberg, Georgios Schoretsanitis, Erich Seifritz et al.
Nitrous oxide (N2O) has been known since the end of the eighteenth century. Today, N2O plays a huge role as a greenhouse gas and an ozone-depleting stratospheric molecule. The main sources of anthropogenic N2O emissions are agriculture, fuel combustion, wastewater treatment, and various industrial processes. By contrast, the contribution of medical N2O to the greenhouse effect appears to be...
BMJ Open
July 16, 2025
Golo Kronenberg, Anna Bankwitz, Barbora Provaznikova et al.
Suicidal thoughts and behaviours are linked to a wide range of mental health conditions. New interest in the psychiatric benefits of nitrous oxide (N2O) has only recently emerged. The broad pharmacological effects of N2O are thought to be due in large part to N-methyl-d-aspartate antagonism and opioid effects. The purpose of this study protocol is to test whether inhalational N2O exerts rapid...
Psychiatry research. Neuroimaging
July 1, 2025
Anna Monn, Corinne Eicher, Annia Rüesch et al.
2 citations
Treatment-resistant depression (TRD) is associated with reduced quality of life and elevated mortality, posing a major challenge to psychiatric care. After non-response to conventional treatments, next-level interventions such as (es)ketamine are recommended, though remission rates remain variable. Identifying reliable markers of treatment response is therefore critical. Recent evidence...
Behavioral sciences (Basel, Switzerland)
August 16, 2024
Judith Rohde, Elena Hickmann, Marco Buchmann et al.
7 citations
This pilot case series investigated the feasibility and efficacy of an eight-week therapy program, combining nasally administered ketamine (0.5 mg/kg) with trauma-focused psychotherapy, for individuals with chronic, treatment-resistant post-traumatic stress disorder (PTSD). Three patients with chronic, treatment-resistant PTSD underwent the eight-week therapy program. Clinical assessments...
Journal of Psychiatric Research
May 1, 2024
Michael Colla, Benjamin Offenhammer, Hanne Scheerer et al.
23 citations
We investigated the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in patients suffering from treatment-resistant depression (TRD) as add-on therapy. Patients were randomized to an additional 160 mg/day or 240 mg/day KET01 or placebo for 14 days. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from...
Frontiers in Behavioral Neuroscience
December 3, 2021
Michael Colla, Hanne Scheerer, Steffi Weidt et al.
9 citations
The serendipitous discovery of ketamine's antidepressant effects represents one of the major landmarks in neuropsychopharmacological research of the last 50 years. Ketamine provides an exciting challenge to traditional concepts of antidepressant drug therapy, producing rapid antidepressant effects seemingly without targeting monoaminergic pathways in the conventional way. In consequence, the...
The Journal of Nervous and Mental Disease
August 1, 2001
Michael Schredl, Golo Kronenberg, Patrick Nonnell et al.
46 citations
Schredl, Michael Ph.D.; Kronenberg, Golo M.D.; Nonnell, Patrick; Heuser, Isabella M.D. Author Information